RJFSA
CLDX icon

Raymond James Financial Services Advisors’s Celldex Therapeutics CLDX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,180
Closed -$508K – 3312
2021
Q2 		$508K Sell
15,180
-71
-0.5% -$1.95K ﹤0.01% 2356
2021
Q1 		$314K Buy
15,251
+71
+0.5% +$1.63K ﹤0.01% 2595
2020
Q4 		$266K Sell
15,180
-20
-0.1% -$360 ﹤0.01% 2536
2020
Q3 		$225K Sell
15,200
-200
-1% -$2.34K ﹤0.01% 2464
2020
Q2 		$200K Sell
15,400
-1,586
-9% -$7.03K ﹤0.01% 2496
2020
Q1 		$28K Buy
16,986
+46
+0.3% +$104 ﹤0.01% 2349
2019
Q4 		$38K Hold
16,940
– – ﹤0.01% 2779
2019
Q3 		$36K Hold
16,940
– – ﹤0.01% 2721
2019
Q2 		$45K Buy
+16,940
New +$57.5K ﹤0.01% 2751
2019
Q1 		– Sell
-1,942
Closed -$6K – 2812
2018
Q4 		$6K Sell
1,942
-5
-0.3% -$25 ﹤0.01% 2550
2018
Q3 		$13K Buy
1,947
+155
+9% +$1.08K ﹤0.01% 2781
2018
Q2 		$14K Sell
1,792
-67
-4% -$896 ﹤0.01% 2738
2018
Q1 		$65K Hold
1,859
– – ﹤0.01% 2426
2017
Q4 		$79K Buy
1,859
+67
+4% +$2.87K ﹤0.01% 2399
2017
Q3 		$77K Hold
1,792
– – ﹤0.01% 2419
2017
Q2 		$66K Sell
1,792
-134
-7% -$5.93K ﹤0.01% 2383
2017
Q1 		$104K Buy
1,926
+400
+26% +$20.8K ﹤0.01% 2258
2016
Q4 		$81K Sell
1,526
-347
-19% -$19.7K ﹤0.01% 2209
2016
Q3 		$114K Buy
1,873
+656
+54% +$40.9K ﹤0.01% 2137
2016
Q2 		$80K Buy
+1,217
New +$77.3K ﹤0.01% 2127

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Raymond James Financial Services Advisors's CLDX Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Celldex Therapeutics (CLDX) in Q3 2021, closing a stake of 15,180 shares — an estimated $508K sold.

Raymond James Financial Services Advisors first reported a position in CLDX in Q2 2016 and held it in 20 quarters. The position peaked at $508K in Q2 2021. 160 funds tracked by Wall St. Rank hold CLDX as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Celldex Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 15,180 Celldex Therapeutics shares in Q3 2021, an estimated $508K.
  • Raymond James Financial Services Advisors first reported a position in Celldex Therapeutics in Q2 2016 and held it in 20 quarters.
  • Raymond James Financial Services Advisors's Celldex Therapeutics position peaked at $508K in Q2 2021.
  • 160 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.